Amgen’s Playing To Its R&D Strengths, Which No Longer Include Neuroscience

Amgen Inc. has never claimed to be an expert in neuroscience, even though it brought the first new migraine drug in decades to the market last year, so the company’s recent decision to end nearly all neuroscience research and development isn’t entirely surprising. It still is notable given the facts that Amgen partnered with Novartis AG a few years ago to expand its efforts in neuroscience, unmet need remains and investment continues in the space – although Pfizer Inc. made a similar exit early last year.

With the migraine prophylactic Aimovig (erenumab) on the market and the discontinuation of development for the Novartis-partnered BACE inhibitor CNP520 in Alzheimer’s disease in July, Amgen has no notable neuroscience programs left in its pipeline